TRIAL DETAIL
A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1/2 |
Start Date 12/13/2019 |
Age of Trial (yrs) 4.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PD-L1 inhibitor + TKI |
|||
Strategy: |
Immune checkpoint inhibitor enhanced by TKI |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CS1001/Regorafenib-101 |
|||
Sponsor: |
CStone Pharmaceuticals |
|||
Patient Contact: |
Wendie Yuan
+86 21 61097678
cstonera@cstonepharma.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral
Intravenous |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
520 South Road |
Kurrulta Park |
South Australia |
5037 |
Australia |